APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acute Myeloid Leukaemia Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Acute Myeloid Leukaemia Therapeutics Market Outlook and Growth Opportunities 2026

4 March 2026191 pages

Choose your research edition.

Industry ResearchAcute Myeloid Leukaemia Therapeutics Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Myeloid Leukaemia Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Acute Myeloid Leukaemia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Myeloid Leukaemia Therapeutics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Myeloid Leukaemia Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Acute Myeloid Leukaemia Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Acute Myeloid Leukaemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Acute Myeloid Leukaemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Acute Myeloid Leukaemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Acute Myeloid Leukaemia Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Acute Myeloid Leukaemia Therapeutics market include Pfizer Inc., Novartis AG, Celgene Corporation, Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals, Boehringer Ingelheim International GmbH, Johnson & Johnson and Gilead Sciences, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Acute Myeloid Leukaemia Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Acute Myeloid Leukaemia Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Acute Myeloid Leukaemia Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Acute Myeloid Leukaemia Therapeutics market.

Acute Myeloid Leukaemia Therapeutics Segment by Company

Pfizer Inc.

Novartis AG

Celgene Corporation

Astellas Pharma Inc.

Daiichi Sankyo Company, Limited

Jazz Pharmaceuticals

Boehringer Ingelheim International GmbH

Johnson & Johnson

Gilead Sciences, Inc.

Amgen Inc.

Takeda Pharmaceutical Company Limited

Sunesis Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Acute Myeloid Leukaemia Therapeutics Segment by Type

Chemotherapy

Targeted Therapy

Immunotherapy

Hypomethylating Agents

Others

Acute Myeloid Leukaemia Therapeutics Segment by Application

Specialty Clinics

Hospital

Others

Acute Myeloid Leukaemia Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Acute Myeloid Leukaemia Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Acute Myeloid Leukaemia Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Acute Myeloid Leukaemia Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Acute Myeloid Leukaemia Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Acute Myeloid Leukaemia Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Acute Myeloid Leukaemia Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Myeloid Leukaemia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Myeloid Leukaemia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Myeloid Leukaemia Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Acute Myeloid Leukaemia Therapeutics industry.

Chapter 3: Detailed analysis of Acute Myeloid Leukaemia Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Acute Myeloid Leukaemia Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Acute Myeloid Leukaemia Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Acute Myeloid Leukaemia Therapeutics Industry Trends Table 2. Acute Myeloid Leukaemia Therapeutics Industry Drivers Table 3. Acute Myeloid Leukaemia Therapeutics Industry Opportunities and Challenges Table 4. Acute Myeloid Leukaemia Therapeutics Industry Restraints Table 5. Global Acute Myeloid Leukaemia Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Acute Myeloid Leukaemia Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Acute Myeloid Leukaemia Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Acute Myeloid Leukaemia Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Acute Myeloid Leukaemia Therapeutics Company, Product Type & Application Table 10. Global Acute Myeloid Leukaemia Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Acute Myeloid Leukaemia Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Chemotherapy Table 15. Significant Companies of Targeted Therapy Table 16. Significant Companies of Immunotherapy Table 17. Significant Companies of Hypomethylating Agents Table 18. Significant Companies of Others Table 19. Global Acute Myeloid Leukaemia Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Acute Myeloid Leukaemia Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Acute Myeloid Leukaemia Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type (2021-2026) Table 23. Global Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Specialty Clinics Table 25. Significant Companies of Hospital Table 26. Significant Companies of Others Table 27. Global Acute Myeloid Leukaemia Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Acute Myeloid Leukaemia Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Acute Myeloid Leukaemia Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application (2021-2026) Table 31. Global Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application (2027-2032) Table 32. Global Acute Myeloid Leukaemia Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Acute Myeloid Leukaemia Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Acute Myeloid Leukaemia Therapeutics Sales Value Share by Region (2021-2026) Table 35. Global Acute Myeloid Leukaemia Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Acute Myeloid Leukaemia Therapeutics Sales Value Share by Region (2027-2032) Table 37. Global Acute Myeloid Leukaemia Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Acute Myeloid Leukaemia Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Acute Myeloid Leukaemia Therapeutics Sales Value Market Share by Country (2021-2026) Table 40. Global Acute Myeloid Leukaemia Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Acute Myeloid Leukaemia Therapeutics Sales Value Market Share by Country (2027-2032) Table 42. Pfizer Inc. Company Information Table 43. Pfizer Inc. Business Overview Table 44. Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 46. Pfizer Inc. Recent Development Table 47. Novartis AG Company Information Table 48. Novartis AG Business Overview Table 49. Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Novartis AG Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 51. Novartis AG Recent Development Table 52. Celgene Corporation Company Information Table 53. Celgene Corporation Business Overview Table 54. Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 56. Celgene Corporation Recent Development Table 57. Astellas Pharma Inc. Company Information Table 58. Astellas Pharma Inc. Business Overview Table 59. Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 61. Astellas Pharma Inc. Recent Development Table 62. Daiichi Sankyo Company, Limited Company Information Table 63. Daiichi Sankyo Company, Limited Business Overview Table 64. Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 66. Daiichi Sankyo Company, Limited Recent Development Table 67. Jazz Pharmaceuticals Company Information Table 68. Jazz Pharmaceuticals Business Overview Table 69. Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 71. Jazz Pharmaceuticals Recent Development Table 72. Boehringer Ingelheim International GmbH Company Information Table 73. Boehringer Ingelheim International GmbH Business Overview Table 74. Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 76. Boehringer Ingelheim International GmbH Recent Development Table 77. Johnson & Johnson Company Information Table 78. Johnson & Johnson Business Overview Table 79. Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 81. Johnson & Johnson Recent Development Table 82. Gilead Sciences, Inc. Company Information Table 83. Gilead Sciences, Inc. Business Overview Table 84. Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 86. Gilead Sciences, Inc. Recent Development Table 87. Amgen Inc. Company Information Table 88. Amgen Inc. Business Overview Table 89. Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 91. Amgen Inc. Recent Development Table 92. Takeda Pharmaceutical Company Limited Company Information Table 93. Takeda Pharmaceutical Company Limited Business Overview Table 94. Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 96. Takeda Pharmaceutical Company Limited Recent Development Table 97. Sunesis Pharmaceuticals, Inc. Company Information Table 98. Sunesis Pharmaceuticals, Inc. Business Overview Table 99. Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 101. Sunesis Pharmaceuticals, Inc. Recent Development Table 102. Agios Pharmaceuticals, Inc. Company Information Table 103. Agios Pharmaceuticals, Inc. Business Overview Table 104. Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 106. Agios Pharmaceuticals, Inc. Recent Development Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Acute Myeloid Leukaemia Therapeutics Product Image Figure 2. Global Acute Myeloid Leukaemia Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Myeloid Leukaemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Acute Myeloid Leukaemia Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Chemotherapy Image Figure 8. Targeted Therapy Image Figure 9. Immunotherapy Image Figure 10. Hypomethylating Agents Image Figure 11. Others Image Figure 12. Global Acute Myeloid Leukaemia Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Acute Myeloid Leukaemia Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type (2021-2032) Figure 15. Specialty Clinics Image Figure 16. Hospital Image Figure 17. Others Image Figure 18. Global Acute Myeloid Leukaemia Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Acute Myeloid Leukaemia Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application (2021-2032) Figure 21. Global Acute Myeloid Leukaemia Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Acute Myeloid Leukaemia Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Acute Myeloid Leukaemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. North America Acute Myeloid Leukaemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Acute Myeloid Leukaemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Acute Myeloid Leukaemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Acute Myeloid Leukaemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 30. South America Acute Myeloid Leukaemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hypomethylating Agents
  • Others
Applications
  • Specialty Clinics
  • Hospital
  • Others
Companies covered
  • Pfizer Inc.
  • Novartis AG
  • Celgene Corporation
  • Astellas Pharma Inc.
  • Daiichi Sankyo Company, Limited
  • Jazz Pharmaceuticals
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Sunesis Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Acute Myeloid Leukaemia Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Acute Myeloid Leukaemia Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Acute Myeloid Leukaemia Therapeutics Market Dynamics
  1. 2.1 Acute Myeloid Leukaemia Therapeutics Industry Trends
  2. 2.2 Acute Myeloid Leukaemia Therapeutics Industry Drivers
  3. 2.3 Acute Myeloid Leukaemia Therapeutics Industry Opportunities and Challenges
  4. 2.4 Acute Myeloid Leukaemia Therapeutics Industry Restraints
3 Acute Myeloid Leukaemia Therapeutics Market by Company
  1. 3.1 Global Acute Myeloid Leukaemia Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Acute Myeloid Leukaemia Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Acute Myeloid Leukaemia Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Acute Myeloid Leukaemia Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Acute Myeloid Leukaemia Therapeutics Company Product Type and Application
  6. 3.6 Global Acute Myeloid Leukaemia Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Acute Myeloid Leukaemia Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Acute Myeloid Leukaemia Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Acute Myeloid Leukaemia Therapeutics Market by Type
  1. 4.1 Acute Myeloid Leukaemia Therapeutics Type Introduction
  2. 4.1.1 Chemotherapy
  3. 4.1.2 Targeted Therapy
  4. 4.1.3 Immunotherapy
  5. 4.1.4 Hypomethylating Agents
  6. 4.1.5 Others
  7. 4.2 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Type
  8. 4.2.1 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Type (2021-2032)
  10. 4.2.3 Global Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type (2021-2032)
5 Acute Myeloid Leukaemia Therapeutics Market by Application
  1. 5.1 Acute Myeloid Leukaemia Therapeutics Application Introduction
  2. 5.1.1 Specialty Clinics
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Application
  6. 5.2.1 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application (2021-2032)
6 Acute Myeloid Leukaemia Therapeutics Regional Value Analysis
  1. 6.1 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Acute Myeloid Leukaemia Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Acute Myeloid Leukaemia Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Acute Myeloid Leukaemia Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Acute Myeloid Leukaemia Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Acute Myeloid Leukaemia Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Acute Myeloid Leukaemia Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Acute Myeloid Leukaemia Therapeutics Country-level Value Analysis
  1. 7.1 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Acute Myeloid Leukaemia Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Acute Myeloid Leukaemia Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Acute Myeloid Leukaemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Acute Myeloid Leukaemia Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer Inc.
  2. 8.1.1 Pfizer Inc. Company Information
  3. 8.1.2 Pfizer Inc. Business Overview
  4. 8.1.3 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  6. 8.1.5 Pfizer Inc. Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Acute Myeloid Leukaemia Therapeutics Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Celgene Corporation
  14. 8.3.1 Celgene Corporation Company Information
  15. 8.3.2 Celgene Corporation Business Overview
  16. 8.3.3 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product Portfolio
  18. 8.3.5 Celgene Corporation Recent Developments
  19. 8.4 Astellas Pharma Inc.
  20. 8.4.1 Astellas Pharma Inc. Company Information
  21. 8.4.2 Astellas Pharma Inc. Business Overview
  22. 8.4.3 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  24. 8.4.5 Astellas Pharma Inc. Recent Developments
  25. 8.5 Daiichi Sankyo Company, Limited
  26. 8.5.1 Daiichi Sankyo Company, Limited Company Information
  27. 8.5.2 Daiichi Sankyo Company, Limited Business Overview
  28. 8.5.3 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio
  30. 8.5.5 Daiichi Sankyo Company, Limited Recent Developments
  31. 8.6 Jazz Pharmaceuticals
  32. 8.6.1 Jazz Pharmaceuticals Company Information
  33. 8.6.2 Jazz Pharmaceuticals Business Overview
  34. 8.6.3 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product Portfolio
  36. 8.6.5 Jazz Pharmaceuticals Recent Developments
  37. 8.7 Boehringer Ingelheim International GmbH
  38. 8.7.1 Boehringer Ingelheim International GmbH Company Information
  39. 8.7.2 Boehringer Ingelheim International GmbH Business Overview
  40. 8.7.3 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product Portfolio
  42. 8.7.5 Boehringer Ingelheim International GmbH Recent Developments
  43. 8.8 Johnson & Johnson
  44. 8.8.1 Johnson & Johnson Company Information
  45. 8.8.2 Johnson & Johnson Business Overview
  46. 8.8.3 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product Portfolio
  48. 8.8.5 Johnson & Johnson Recent Developments
  49. 8.9 Gilead Sciences, Inc.
  50. 8.9.1 Gilead Sciences, Inc. Company Information
  51. 8.9.2 Gilead Sciences, Inc. Business Overview
  52. 8.9.3 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  54. 8.9.5 Gilead Sciences, Inc. Recent Developments
  55. 8.10 Amgen Inc.
  56. 8.10.1 Amgen Inc. Company Information
  57. 8.10.2 Amgen Inc. Business Overview
  58. 8.10.3 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  60. 8.10.5 Amgen Inc. Recent Developments
  61. 8.11 Takeda Pharmaceutical Company Limited
  62. 8.11.1 Takeda Pharmaceutical Company Limited Company Information
  63. 8.11.2 Takeda Pharmaceutical Company Limited Business Overview
  64. 8.11.3 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio
  66. 8.11.5 Takeda Pharmaceutical Company Limited Recent Developments
  67. 8.12 Sunesis Pharmaceuticals, Inc.
  68. 8.12.1 Sunesis Pharmaceuticals, Inc. Company Information
  69. 8.12.2 Sunesis Pharmaceuticals, Inc. Business Overview
  70. 8.12.3 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  72. 8.12.5 Sunesis Pharmaceuticals, Inc. Recent Developments
  73. 8.13 Agios Pharmaceuticals, Inc.
  74. 8.13.1 Agios Pharmaceuticals, Inc. Company Information
  75. 8.13.2 Agios Pharmaceuticals, Inc. Business Overview
  76. 8.13.3 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  78. 8.13.5 Agios Pharmaceuticals, Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst